2017
DOI: 10.1073/pnas.1620052114
|View full text |Cite
|
Sign up to set email alerts
|

Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis

Abstract: Despite continuous interest in multiple sclerosis (MS) research, there is still a lack of neuroprotective strategies, because the main focus has remained on modulating the immune response. Here we performed in-depth analysis of neurodegeneration in experimental autoimmune encephalomyelitis (EAE) and in in vitro studies regarding the effect of the well-established L-type calcium channel antagonist nimodipine. Nimodipine treatment attenuated clinical EAE and spinal cord degeneration and promoted remyelination. S… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
64
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 53 publications
(66 citation statements)
references
References 52 publications
2
64
0
Order By: Relevance
“…However, the role of melatonin in long‐range peripheral nerve defect was not discussed before. Appropriate microenvironment is important to correct remyelination and axonal regrowth that can be disturbed by excessive reactive oxygen species, ischemic and inflammatory processes . In this study, we fabricated a 3D melatonin/polycaprolactone nerve guide conduit using multilayer molding method and investigated its effects on Schwann cell proliferation and neural expression in vitro.…”
Section: Introductionmentioning
confidence: 99%
“…However, the role of melatonin in long‐range peripheral nerve defect was not discussed before. Appropriate microenvironment is important to correct remyelination and axonal regrowth that can be disturbed by excessive reactive oxygen species, ischemic and inflammatory processes . In this study, we fabricated a 3D melatonin/polycaprolactone nerve guide conduit using multilayer molding method and investigated its effects on Schwann cell proliferation and neural expression in vitro.…”
Section: Introductionmentioning
confidence: 99%
“…NG2 + cell density was similarly reduced in the corpus callosum of P60 + 10 CaV1.2-deleted mice, when compared to control mice ( Figure S4e-g), confirming that CaV1.2 deletion resulted in OPC loss rather than the loss of PDGFRα expression by OPCs. As this reduction in OPC density was not recapitulated by the partial pharmacological blockade of CaV1.2, achieved by giving daily injections of nimodipine (as per Schampel et al (2017)) for up to seven consecutive days ( Figure S5), it is likely that OPC density can only be compromised by the complete and sustained loss of CaV1.2 signaling, as was achieved by our gene deletion approach.…”
Section: Cav12 Is Essential For the Survival Of Opcs In The Adult mentioning
confidence: 91%
“…j) Quantification of PDGFRα + OPCs density (per mm 2 ; x‐y plane with fixed z‐depth of 30 μm) in the corpus callosum of mice that received vehicle or nimodipine for 4 or 7 days. Schampel et al () reported that nimodipine delivery resulted in the apoptotic loss of microglia from the spinal cord of mice with experimental autoimmune encephalomyelitis, but not from healthy mice. We confirm that nimodipine does not alter microglial number in the spinal cord or brain of healthy mice.…”
mentioning
confidence: 99%
“…; Schampel et al . ). For reasons that are not well understood, remyelination is incomplete in most of MS patients (Patrikios et al .…”
mentioning
confidence: 97%
“…On the cellular levels, steps involved in remyelination include the activation and proliferation of oligodendrocyte progenitor cells (OPCs), the migration of these OPCs toward the demyelinated axon, and the interaction of OPCs with the axon, which culminates in OPC differentiation and finally remyelination. The beneficial effects of remyelination are well known and include the restoration of axonal conduction properties that are lost following demyelination (Honmou et al 1996) as well as axonal protection (Funfschilling et al 2012;Moore et al 2013;Schampel et al 2017). For reasons that are not well understood, remyelination is incomplete in most of MS patients (Patrikios et al 2006), and remyelination efficacy decreases with age (Sim et al 2002).…”
mentioning
confidence: 99%